AbbVie's Rinvoq expansion hits a 2nd snag as FDA delays $2B atopic dermatitis ruling

AbbVie has pegged multibillion-dollar hopes on Rinvoq to fill the revenue gap when immunology superstar Humira loses U.S. market exclusivity. But that plan, dependent on multiple label expansions, has hit its second regulatory setback in weeks.